Title: Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32.
1443138-53-1 | GSK2200150A | AA01EOPD | MFCD28160555
1797986-63-0 | α-phenyl-β-propyl-1-pyrrolidineethanol,2,2,2-trifluoroacetatesalt | AA01EOXT
1616469-10-3 | 3,3,4-trimethyl-1-(1-(2-morpholinoethyl)-1H-indol-3-yl)pent-4-en-1-one | AA01EP8P
186501-28-0 | N-[2-[(acetyloxy)methoxy]-2-oxoethyl]-N-[2-[2-[5-[[[3',6'-bis(acetyloxy)-2',7'-dichloro-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl]carbonyl]amino]-2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]phenoxy]ethoxy]phenyl]-glycine,(acetyloxy)methylester | AA01EPGE
822-18-4 | 9Z,12Z,15Z-octadecatrienoicacid,monosodiumsalt | AA01EPLL
1478712-37-6 | 2-methoxy-6-[6-methoxy-4-[[5-methyl-2-(4-morpholinyl)-4-thiazolyl]methoxy]-2-benzofuranyl]-imidazo[2,1-b]-1,3,4-thiadiazole | AA01EPSL | MFCD30532696
1820596-85-7 | (2R,2'R,2''R,3S,3'S,3''S,4S,4'S,4''S,5R,5'R,5''R,6R,6'R,6''R)-6,6',6''-(((((72-(heptyloxy)-12,32,52-trimethoxy-1,3,5,7(1,3)-tetrabenzenacyclooctaphane-15,35,55-triyl)tris(ethane-2,1-diyl))tris(1H-1,2,3-triazole-1,4-diyl))tris(methylene))tris(oxy))tris(2-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol) | AA01EQ1L
416876-71-6 | N-(2-fluorophenyl)-1-(phenylmethyl)-4-piperidinamine | AA01EQ8D
1409931-99-2 | HS666hydrochloride | AA01EQD6
1212432-27-3 | (1S,4S)-2-Methylbicyclo[2.2.1]hept-5-ene-2-carboxylic acid | AA01EQXA | MFCD18380392
